Do physicians or insurers decide which medicine is best for a patient? For years, insurers have employed utilization management tools that limit patient access to new therapeutics to control costs with the result of keeping many innovative treatments from patients who do not have resources to go outside insurance coverage for the best and most appropriate care. This panel will discuss the use of step therapy by payers and how it can undermine the doctor/patient relationship and what policies need to change to put the physician and patient back in the driver’s seat of their care.
A TED style talk given by an industry professional.
Sponsored by BIO
How will we successfully navigate the post-pandemic life science business landscape? If you could find the reset button, would you use it? 2020-2023 has brought both pain and profound acceleration, fundamentally transforming the way we work. Dennis will touch upon the challenges and accelerators that affect the current state of the industry, reflect on these pivotal influences, and share his thoughts on what they means for the immediate future.
Sponsored by Eppendorf
The proliferation of AI technology has created both exciting opportunities for product and device development as well as increased scrutiny by federal agencies of how these technologies will be built and used. In this panel, we will discuss the ways in which AI can promote new avenues of treatment through advances in product and device development. Generative AI, in particular, has the potential to revolutionize product and device development by shortening the design timeframe, and to create efficiencies in clinical trials for devices by using algorithms to collect patient data more efficiently. We will also discuss the importance of ensuring elimination of bias in data collection to promote reliable algorithms and will outline lessons learned as well as upcoming challenges and opportunities in the use of AI.
Sponsored by Moses Singer
After a decades long decline, deaths from cardiovascular disease (CVD) are once again on the rise and today, CVD is leading cause of death in the United States. And that rate is even higher amongst certain populations – including women, racial minorities, and rural populations. This session will provide critical background and context on the challenges before us; its impact on families, communities, and state economies across our country; and policy changes that could help to finally curb our current trajectory and improve the lives of the 30 million patients currently diagnosed with heart disease.
Sponsored by Novartis
This panel will take the lessons learned from COVID vaccine development and the accompanying medical, political and community conversations to discuss the horizon for vaccines.
Sponsored by Merck
Funding is fuel for innovation. What’s the investment outlook for biotech companies based on the current funding environment—and what can you do to improve your opportunities? Learn what it means to be “diligence ready” so you and your company are positioned for success.
Sponsored by EisnerAmper
Whether it’s the first-time raising capital or you’re ready to go public, connecting with investors in way that resonates can be the difference between moving your pipeline forward or shutting your doors, particularly in today’s unpredictable market. MacDougall’s Sara Michelmore will sit down with panelists to hear more about what is required to secure your next round of funding.
Sponsored by MacDougall
Holly is the current Alliance Development Manager for New York at Pfizer. In her role as ADM Holly collaborates with patient advocacy groups and medical societies to advance healthcare policy to improve access to care. In her spare time, Holly volunteers at the Open Door Clinic, a free health clinic for uninsured and under-insured adults in Addison County, Vermont, where she resides with her family. Holly has more than 15 years experience in the biotech industry and received a Healthcare MBA with an emphasis in Health Policy from Oregon Health and Science University in 2014.More information about speaker
Alison Dwyer Hoke is a pharmacist for Kinney Drugs in Syracuse, New York. Previously, she co-founded Two Smiles One Hope Foundation which raised money for advocacy and education for Duchenne muscular dystrophy, a fatal neuromuscular disease that affects her twin sons. As an advocate, pharmacist, and full-time caregiver, Alison is involved in various areas of rare disease and accessibility advocacy. She resides in Cazenovia, New York with her husband and sons.More information about speaker
Energizing New York City's Life Science Ecosystem
Sponsored by JLABS
Jennifer Hawks Bland is the Chief Executive Officer of NewYorkBIO. Prior to joining NewYorkBIO, Ms. Bland was an Executive Director in the State Government Affairs & Policy group at Merck. She has also held government affairs positions at GlaxoSmithKline and the Consumer Healthcare Products Association (CHPA), the 136-year old trade association representing manufacturers of over-the- counter medicines. Ms. Bland previously was an associate with the Jackson, MS law firm of Butler, Snow, O’Mara, Stevens, & Cannada, PLLC where she principally practiced in the area of products liability litigation. Before entering the practice of law, she worked for six years for U.S. Senator Thad Cochran (RMiss.). Ms. Bland is a member of both the District of Columbia and Mississippi Bar Associations. She also has extensive volunteer experience and is currently the PTA co-president of her child’s school and sits on the Board of the Pelham Art Center. Ms. Bland currently resides in Pelham, New York with her husband, R. Trabue Bland and their two sons.More information about speaker